• Non ci sono risultati.

Scarica il programma in formato PDF

N/A
N/A
Protected

Academic year: 2022

Condividi "Scarica il programma in formato PDF"

Copied!
4
0
0

Testo completo

(1)

INNOVATORS

IN BREAST CANCER

Chairman Alessandra Gennari Course Director Alessandra Gennari and Filippo Montemurro

Con il patrocinio

26-27 OCTOBER 2018

BAVENO

CONVENTION CENTER HOTEL DINO

(2)

Chairman Alessandra Gennari

10.30 Welcome Coffee

10.45 Welcome address by Authorities

11.00 Introduction to the conference Alessandra Gennari 11.20 Breast Cancer: where are we going?

Moderators: Alessandra Gennari, Filippo Montemurro Lecture: Nadia Harbeck 11.40 Molecular Biology

Moderators: Renzo Boldorini, Alessandra Gennari From biology to genomics Giuseppe Viale

From biology to imaging Carolien Schroder

12.20 Adjuvant Therapy in Early Breast Cancer: The concept of De-escalation Moderators: Fabio Puglisi, Paolo Marchetti

Pros: Pierfranco Conte Cons: Javier Cortes 13.10 – 14.30 Lunch

14.30 Breast cancer prognosis: true improvement?

Moderators: Paolo Pronzato, Mario Airoldi Lecture: Paolo Bruzzi Discussion

15.00 Breast cancer in the elderly

Moderators: Gian Carlo Avanzi, Pierfranco Conte Ageing and cancer Alberto Pilotto

Comprehensive Geriatric Assessment Etienne Brain Discussion

16.00 – 16.20 Coffee Break

16.20 - 17.00 Academic associations: role in society and research Moderators: Chiara Saggia, Fulvia Pedani Women For Oncology Valentina Guarneri ANDOS Fulvia Pedani

AIRC Lisa Vozza 17.00 - 18.30 Women and science

Presenters: Alessandra Gennari, Fedro Peccatori Paolo Veronesi Lucia Del Mastro Clifford Hudis Dino Amadori

Nadia Bordoli Claudia Hausmann

INNOVATORS

IN BREAST CANCER BAVENO

FRIDAY

26 OCTOBER S

(3)

9.00 – 9.50 ESMO News

Moderators: Alessandra Gennari, Filippo Montemurro Early Breast Cancer Grazia Arpino

Advanced Breast Cancer Alessandra Fabi

Take home messages from ESMO Evandro De Azambuja Discussion

9.50 New drugs: Pharmacological interactions and toxicities Moderators: Marco Krengli, Pierluigi Canonico New PK Intercations Romano Danesi

New Drugs and the Heart Giorgio Minotti Trastuzumab and Heart Michael Ewer

Cardiac toxicity in the elderly Daniela Cardinale

Drug Sustainability and Regulatory Issues in Breast Cancer Armando Genazzani Discussion

11.10 – 11.30 Coffee Break 11.30 – 12.20

Controversy: Immunotherapy in breast cancer

Moderators: Filippo Montemurro, Ornella Garrone Pros: Giuseppe Curigliano Cons: Fabrice Andrè Take Home Message Michelino De Laurentiis

Discussion

12.20 Round Table: The future of Breast Cancer Research: Young Oncologist Perspective Moderators: Valentina Rossi, Andrea Rocca

Rachel Wuerstlein Matteo Lambertini Carmen Criscitiello Tom Degenhardt Andrea Milani 12.50 – 13.00

Conclusions Alessandra Gennari, Filippo Montemurro 13.00 Lunch

SATURDAY

27 OCTOBER

(4)

Chairman Alessandra Gennari

Scientific Secretariat Chiara Saggia, Andrea Milani Venue Convention Center Hotel Dino

Corso Giuseppe Garibaldi, 20 28831 Baveno VB

tel. +39 0323 922201

Registration includes participation to the scientific sessions, certificate of attendance, lunches, coffee breaks and Social dinner on october 26th

€ 350,00 (VAT 22% not included)

CME The program of INNOVATORS IN BREAST CANCER is credited for the Italian Continuing Medical Education (CME/ECM) for 120 Italian Physicians (Oncology, Internal Medicine, Radiology, Radiotherapy, Hematology, Surgery, Pathological anatomy, Plastic Surgery, Obstetrics and Gynecology)

CME credits: n° 6,3 ID. event 486-231662

We remind that the acquisition of CME credits is subject to at least 90% of the actual attendance of the training program and the evaluation test must be passed with a percentage of correct answers not less than 75% of the total of the questions.

Organizing Secretariat and Provider

Symposia Organizzazione Congressi Srl Palazzo del Melograno

Campetto, 2/8 - 16123 Genova

Tel: +39 010 255146 - Fax: +39 010 2770565 [email protected]

www.symposiacongressi.com

Invited Faculty

AIROLDI MARIO TORINO

AMADORI DINO MELDOLA ANDRÈ FABRICE VILLEJUIF F

ARPINO GRAZIA NAPOLI AVANZI GIANCARLO NOVARA

BOLDORINI RENZO NOVARA

BORDOLI NADIA MILANO

BRAIN ETIENNE SAINT CLOUD

BRUZZI PAOLO GENOVA

CANONICO PIER LUIGI NOVARA

CARDINALE DANIELA MILANO

CONTE PIERFRANCO PADOVA CORTES JAVIER BARCELONA CRISCITIELLO CARMEN MILANO CURIGLIANO GIUSEPPE MILANO

DE AZAMBUJA EVANDRO BRUSSELS

DE LAURENTIIS MICHELINO NAPOLI

DEL MASTRO LUCIA GENOVA

DANESI ROMANO PISA

DEGENHARDT TOM MUNICH

EWER MICHAEL HOUSTON

FABI ALESSANDRA ROMA

GARRONE ORNELLA CUNEO GENAZZANI ARMANDO NOVARA GENNARI ALESSANDRA NOVARA

GUARNERI VALENTINA PADOVA

HARBECK NADIA MUNICH

HAUSMANN CLAUDIA ROMA

HUDIS CLIFFORD ALEXANDRIA

KRENGLI MARCO NOVARA

LAMBERTINI MATTEO BRUSSELS

MARCHETTI PAOLO ROMA

MILANI ANDREA CANDIOLO MINOTTI GIORGIO ROMA MONTEMURRO FILIPPO CANDIOLO PECCATORI FEDRO MILANO

PEDANI FULVIA TORINO

PILOTTO ALBERTO GENOVA

PRONZATO PAOLO GENOVA

PUGLISI FABIO UDINE

ROCCA ANDREA MELDOLA

ROSSI VALENTINA NOVARA

SAGGIA CHIARA NOVARA

SCHRODER CAROLIEN GRONINGEN VERONESI PAOLO MILANO VIALE GIUSEPPE MILANO

VOZZA LISA MILANO

WUERSTLEIN RACHEL MUNICH

Riferimenti

Documenti correlati

Objectives To build a machine learning (ML) model to detect extraprostatic extension (EPE) of prostate cancer (PCa), based on radiomics features extracted from prostate MRI

Moreover we illustrate the state of the art of digital mammographic imaging systems and discuss how new technologies, such as pixel semiconductor detectors and Single Photon

Adjuvant chemo- therapy for early breast cancer in patients under 50 years old reduces the relative risk of recurrence by 35% and death by 27%, and for patients with

biopsy (including skin) through reddened area and include adjacent normal skin (some recommend FNA because clinical grounds confirm stage of dis- ease and you just want a dx of

Abnormal hypermetabolism involving the bilateral high internal mammary and right paratracheal lymph nodes at the level of the AP window, consistent with metastatic disease..

The goal of minimally invasive therapy for breast cancer is to eradicate cancer cells with minimal damage to the underlying normal breast parenchyma or skin.. Tumor ablation is seen

· For ductal carcinoma in situ (DCIS) cases with minor extension upto 2.5, exclusion of sentinel node involvement should be recommended, be- cause minimal invasion not suggested by

The focus of this chapter is to highlight recent advances in breast cancer research using microarray technology to (1) establish more precise molecular profiles for